Global Bevacizumab Biosimilar
Market by Application spans Analytical, Pharmacokinetic, Clinical Data,
Pharmacology, and Toxicology Data. Currently, there is no acknowledged
biosimilar for bevacizumab, a monoclonal antibody used for treating advanced
solid tumors, counting metastatic colorectal cancer (mCRC) and advanced or
metastatic non-squamous non-small-cell lung cancer (mNSCLC).
Bevacizumab is a humanized
monoclonal antibody. It constrains angiogenesis (the formation of new blood
vessels) by blocking the action of vascular endothelial growth factor A
(VEGF-A). Bevacizumab can accordingly slow the growth of new blood vessels in
tumor’s and is used to treat various cancers, including colorectal, lung,
breast, glioblastoma, kidney and ovarian.
View Full Report with TOC @ https://www.millioninsights.com/industry-reports/bevacizumab-biosimilar-market
In the United States, it is
accepted for giving glioblastoma (GBM) and metastatic ovarian cancer (mOC), and
in the European Union (EU) it is indicated for patients with metastatic breast
cancer (mBC). Bevacizumab has been exposed to prolong existence in patients
with these cancers when combined with chemotherapy in the global Bevacizumab
Biosimilar Industry. The measured physicians who did not regularly endorse
bevacizumab, those from emerging markets were more probable to cite access as a
fence to indorsing across all tumors types. Further, physicians in the United
States and EU found it easier to access the drug when treating patients with
mCRC, mNSCLC, and mOC than physicians in emerging markets.
U.S. physicians could
willingly admit bevacizumab for treatment of GBM than physicians in the other
two markets, while EU physicians found it easier to admission the drug for mBC.
The major reasons for the apparent barriers to access were that the drug’s
costs were “not compensated by healthcare system/private insurance,” and the
high out-of-pocket (OOP) costs to the patient. These fences were most commonly
cited by physicians in developing markets, although more than high of American
defendants said lack of repayment was a barrier to recommending the drug for
mOC, associated with 55% of physicians in developing markets and just in the
EU.
Of the physicians who had to
reduce the number of cycles agreed, the most common reason across all markets
and tumor types was the lack of reimbursement. Global Bevacizumab Biosimilar
Market by Geographical Region spans North America, Europe, China, Japan,
Southeast Asia, and India. Global Bevacizumab Biosimilar Industry Key Players
include Pfizer, Allergan, Alnylam Pharmaceuticals, Amgen, Angstrom
Pharmaceuticals, Acceleron Pharma, Biocon, Bionomics, and CASI Pharmaceuticals.
Request a Sample
Copy of This Report @ https://www.millioninsights.com/industry-reports/bevacizumab-biosimilar-market/request-sample
Comments
Post a Comment